New drug DFV890 takes on Hard-to-Treat blood cancers
NCT ID NCT05552469
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called DFV890 in about 62 adults with low-risk myelodysplastic syndromes, low-risk chronic myelomonocytic leukemia, or high-risk clonal cytopenia of undetermined significance. The main goals are to check the drug's safety, find the best dose, and see if it can reduce the need for blood transfusions. Participants will be closely monitored for side effects and how their disease responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DFV890
- What this could lead to
- If successful, this could point toward a new treatment option for certain myeloid blood disorders that currently have limited therapies.
- What could go wrong
- This is an early Phase 1b trial with only 62 participants, so safety and the right dose are still being figured out. It may not lead to an approved treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOWER-RISK MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Cancer Ctr
New York, New York, 10065, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Novartis Investigative Site
Grenoble, 38043, France
-
Novartis Investigative Site
Nantes, 44093, France
-
Novartis Investigative Site
Paris, 75475, France
-
Novartis Investigative Site
Düsseldorf, North Rhine-Westphalia, 40225, Germany
-
Novartis Investigative Site
Dresden, Saxony, 01307, Germany
-
Novartis Investigative Site
Leipzig, Saxony, 04103, Germany
-
Novartis Investigative Site
Lübeck, 23538, Germany
-
Novartis Investigative Site
Hong Kong, 999999, Hong Kong
-
Novartis Investigative Site
Brescia, BS, 25123, Italy
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Cardiff, CF14 4XW, United Kingdom
-
Novartis Investigative Site
London, SE5 9RS, United Kingdom
-
Novartis Investigative Site
Manchester, M20 2BX, United Kingdom
-
Sidney Kimmel CCC At JH
Baltimore, Maryland, 21231, United States
-
Stanford Cancer Center
Stanford, California, 94305, United States
-
Univ of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
-
Vanderbilt University Medical Ctr
Nashville, Tennessee, 37232, United States
-
Weill Cornell Medicine NY-Presb
New York, New York, 10021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.